Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

UVA Health scientists have developed a new, noninvasive way to assess heart health using MRI technology. A few scientists spearheading this latest development say it could lead to better outcomes for ...

Trinity Health Muskegon recently achieved a significant milestone by successfully implanting AVEIR DR, the world’s first dual-chamber leadless pacemaker system designed to effectively treat abnormal ...

Ohio Valley Health Center has reached a significant milestone with the successful completion of its first echocardiogram.This non-invasive ultrasound test, whic ...

Three common heart conditions—heart failure, atrial fibrillation, and coronary heart disease—are closely linked to cognitive decline and a higher risk of dementia, according to a new scientific ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...